Merck has unveiled a new pill that slashes "bad" LDL cholesterol—by at least half in two-thirds of patients, per STAT ...

In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions ...

A new Merck pill called enlicitide slashes levels of harmful LDL cholesterol by up to 60%, similar to injectable PCSK9 drugs ...

The drug targets the PCSK9 protein, and could give millions of people a more affordable option to reduce their heart disease ...

An oral agent is needed because some patients don’t like injectables, and some doctors don’t prescribe them, experts say.

The investigational oral PCSK9 inhibitor enlicitide reduced low-density lipoprotein (LDL) cholesterol in patients with or at ...

In recent days, Merck announced pivotal Phase 3 trial results showing its once-daily oral PCSK9 inhibitor, enlicitide, reduced low-density lipoprotein cholesterol by more than half in patients with ...

A novel once-daily oral PCSK9 inhibitor lowered LDL by up to 60% at 24 weeks in patients with heart disease or at high risk ...

Merck’s pill, which could be the first oral PCSK9 drug to get to market, displayed similar effects on lipid levels as ...

The LDL-C reductions seen with enlicitide in both studies are in the same ballpark as those seen with injectable ...

The cholesterol medication alirocumab, a PCSK9 inhibitor, combined with a statin appeared to reduce LDL cholesterol levels by ...

The medication, which significantly lowers the risk of heart attacks, could be a promising alternative to expensive and ...